{
    "clinical_study": {
        "@rank": "97517", 
        "acronym": "DDandOAT", 
        "arm_group": {
            "arm_group_label": "Oral Anticoagulants--warfarin", 
            "description": "After mechanical valve replacement\uff0cpatients should be gave oral anticoagulants\uff0csuch as warfarin\uff0cto keep International normalized ratio in 2.0 to 3.0\u3002 Warfarin  dosage form 3mg/pill\uff0conce per day\uff0cduring a lifetime\u3002"
        }, 
        "biospec_descr": {
            "textblock": "BLOOD"
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "TO evaluate Whether the D-dimer levels could predict the Subsequent Thromboembolic and\n      Cardiovascular Events in Patients post-mechanical valves replacement during oral\n      anticoagulation therapy."
        }, 
        "brief_title": "D-dimer and Oral Anticoagulation Therapy in Patients With Mechanical Valve Replacement", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Valve Disease", 
        "condition_browse": {
            "mesh_term": "Heart Valve Diseases"
        }, 
        "detailed_description": {
            "textblock": "Patients with mechanical valves replacements need anticoagulation in lifetime,warfarin is\n      the most widely used oral anticoagulants\uff0cand the extent of anticoagulation should suitable\n      and be monitored\uff0cProthrombin time\uff08PT\uff09 derivative International Normalized Ratio(INR)is the\n      best monitor parameter\uff0cand have a well recognized therapy range\uff1a2.0-3.0\u3002 Is it enough only\n      using INR to monitor the anticoagulants therapy\uff1fBecause some clinicians found some patient\n      still have poor prognosis even though their INR were suitable\u3002 This study is to evaluate\n      Whether the D-dimer could be a necessary supplement for INR\uff0cto monitor oral anticoagulation\n      therapy in patients post-mechanical valves replacement."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age>18years,male or female without pregnancy;\n\n          2. Suffered the mechanical valves replacement in Wuhan Asia Heart Hospital;\n\n          3. The operation type was aortic valve replacement and/or Mitral valve replacement .\n\n        Exclusion Criteria:\n\n          1. deep venous thromboembolism\n\n          2. Pulmonary embolism\n\n          3. Aortic dissection\n\n          4. stroke\n\n          5. Cerebral hemorrhage\n\n          6. Myocardial infarction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients suffered mechanical valves replacement because of valves dysfunction; and oral\n        anticoagulation therapy with warfarin"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996657", 
            "org_study_id": "2013-P-002"
        }, 
        "intervention_browse": {
            "mesh_term": "Anticoagulants"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mechanical valves replacement", 
            "INR", 
            "D-dimer", 
            "thromboembolic events"
        ], 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "contact": {
                "email": "zhangleetau@163.com", 
                "last_name": "zhang li tao, MD.P", 
                "phone": "+86 02765796739"
            }, 
            "facility": {
                "address": {
                    "city": "Wuhan", 
                    "country": "China", 
                    "state": "Hubei", 
                    "zip": "430022"
                }, 
                "name": "Wuhan Asia Heart Hospital"
            }, 
            "investigator": {
                "last_name": "zhang li tao, MD.P", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "D-dimer Levels Predict Subsequent Prognosis in Patients Post-mechanical Valves Replacement During Oral Anticoagulation Therapy \uff1aa Prospective Study", 
        "overall_official": [
            {
                "affiliation": "Wuhan Asia Heart Hospital", 
                "last_name": "zhang zhenlu, PH.D", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Wuhan Asia Heart Hospital", 
                "last_name": "Zhou xin, Doctor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Wuhan Asia Heart Hospital", 
                "last_name": "liu ze jin, PH.D", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Thromboembolic Events include venous thromboembolism ,stroke.", 
            "measure": "Thromboembolic Events", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Vascular Events include Cerebral hemorrhage,myocardial infarction \uff0cCardiac death\uff0cUnexplained death.", 
            "measure": "Vascular Events", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "source": "Wuhan Asia Heart Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wuhan Asia Heart Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}